Countdown to the Finals of the ASC24 Student Supercomputer Challenge!
2.4.2024 11:37:00 EEST | Business Wire | Press release
The 2024 ASC Student Supercomputer Challenge (ASC24) finals are scheduled to take place at Shanghai University from April 9 to 13, 2024. Among the over 300 teams representing universities worldwide, only 25 have progressed to the finals. Throughout the competition finals, teams will face a series of challenges including optimizing large language model (LLM) inference, tackling tasks like OpenCAEPoro and GoMars, as well as competing in high-performance benchmarks such as HPL and HPCG. Additionally, teams will engage in group competitions and tackle a mystery application. Each team will present their projects before the jury, contending for prestigious awards including the Champion, Silver Prize, e Prize, and the Highest LINPACK.
The ASC24 Student Supercomputer Challenge Finals
|
Date |
Time |
Agenda |
|
April 9 |
08:00-20:00 |
Rule Announcement, Cluster Setup/Testing |
|
April 10 |
08:00-20:00 |
Cluster Setup/Testing |
|
April 11 |
08:00-18:00 |
Competition: HPL & HPCG, Group Competition, LLM |
|
April 12 |
08:00-18:00 |
Competition: OpenCAEPoro, GoMars, mystery APP |
|
14:00-17:00 |
The 33rd HPC Connection Workshop |
|
|
April 13 |
08:00-12:10 |
Finalist Teams Presentations before the Jury |
|
15:00-17:30 |
Closing and awards ceremony |
ASC is committed to assisting students in addressing state-of-the-art scientific challenges through the utilization of the most advanced computing products and technologies. This endeavor aims to explore emerging research paradigms and confront the various challenges humanity faces. The focal point of the ASC24 finals will revolve around tackling cutting-edge scientific issues, such as advancing large language models (LLM), exploring Mars, and enhancing techniques for oil and gas exploitation.
The prestigious e Prize will be bestowed upon the winners of the OpenCAEPoro task, which entails simulating the seepage of multiphase fluids, such as oil, gas, and water, particularly within contexts relevant to petroleum extraction. Competitors are tasked with skillfully optimizing large-scale parallel computing processes, emphasizing enhancements in computing performance and parallel efficiency of discrete algorithms.
In the GoMars task, participating teams are challenged with optimizing parallel communication and refining computational load balancing within the dynamic framework of GoMars. GoMars represents a new generation of Mars atmosphere models. The objective is to enhance operational efficiency and achieve more precise predictions of the Martian atmosphere.
In the LLM Inference Optimization Challenge, participating teams are assigned the task of constructing and refining inference engines utilizing the widely employed open-source LLM, AquilaChat2-34B. The primary objective is to expedite inference processes by employing 4-bit or less quantization while maintaining overall accuracy.
Alongside the primary challenges, the finals will include a Group Competition aimed at fostering cross-team collaboration among students. Students will be randomly allocated to one of five groups. Each group will work collectively on the ParaSeis task, employing ParaSeis to simulate seismic wave propagation and refine the algorithm through collaborative communication. The group's performance will be evaluated based on the average score of its constituent teams, with the group achieving the highest score declared as the victor.
The finals will bring together formidable teams from renowned universities, including Peking University - the champion of the 10th ASC onsite finals, the Chinese University of Hong Kong - the champion of the 10th ASC virtual finals, University of Science and Technology of China, Huazhong University of Science and Technology, Shanghai Jiao Tong University, and Friedrich-Alexander-University Erlangen-Nuremberg.
Numerous new teams are set to join the finals, with Shanghai University, Lanzhou University, and Southern University of Science and Technology among them. Excitement surrounds the debut of teams from the National University of Cordoba, Macau University of Science and Technology, and Southwest Petroleum University, making their inaugural ASC finals appearance this year. The enthusiasm of these new contenders promises to elevate the competition, ensuring an intense battle until the very end.
About ASC
The ASC Student Supercomputer Challenge is the world's largest student supercomputer competition, sponsored and organized by the Asia Supercomputer Community with support from experts and institutions across Asia, Europe, and America. The main objectives of ASC are to encourage the exchange and training of young supercomputing talent from different countries, improve supercomputing applications and R&D capacity, boost the development of supercomputing, and promote technical and industrial innovation. The first ASC Student Supercomputer Challenge was held in 2012 and has since attracted over 10,000 undergraduates from all over the world. Learn more for ASC at http://www.asc-events.net/StudentChallenge/index.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402763009/en/
Contact information
Media
media@asc-events.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
